IQVIA Holdings (IQV) Gets a Hold from Citi
Citi analyst Patrick B Donnelly maintained a Hold rating on IQVIA Holdings yesterday and set a price target of $200.00. The company’s shares closed yesterday at $170.64.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, B Donnelly is a 3-star analyst with an average return of 2.7% and a 47.13% success rate. B Donnelly covers the Healthcare sector, focusing on stocks such as Qiagen, Bruker, and Thermo Fisher.
In addition to Citi, IQVIA Holdings also received a Hold from TipRanks – Google’s Google Medical – Diagnostics and Research in a report issued today. However, on the same day, TipRanks – PerPlexity upgraded IQVIA Holdings (NYSE: IQV) to a Buy.
Based on IQVIA Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.36 billion and a net profit of $514 million. In comparison, last year the company earned a revenue of $3.96 billion and had a net profit of $437 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IQV in relation to earlier this year. Most recently, in December 2025, Ari Bousbib, the Chairman, CEO & President of IQV sold 36,564.00 shares for a total of $8,132,930.52.
Read More on IQV:
Disclaimer & DisclosureReport an Issue
- Iqvia to acquire certain discovery services assets from Charles River
- Iqvia price target lowered to $215 from $266 at Mizuho
- Iqvia price target lowered to $245 from $290 at Truist
- Iqvia price target lowered to $174 from $245 at TD Cowen
- IQVIA: Solid 2026 Outlook but AI Disruption Risks Justify Hold Rating and Lowered Valuation
